Sanuwave Health (SNWV) Set to Announce Quarterly Earnings on Friday

Sanuwave Health (NASDAQ:SNWV) is projected to issue its Q3 2026 resultson Friday, November 6th. Analysts expect Sanuwave Health to post earnings of $0.01 per share and revenue of $13.75 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05). The business had revenue of $9.74 million for the quarter, compared to analyst estimates of $11.50 million. Sanuwave Health had a return on equity of 1,728.10% and a net margin of 32.38%.

Sanuwave Health Stock Up 1.4%

NASDAQ:SNWV opened at $5.93 on Wednesday. Sanuwave Health has a twelve month low of $3.92 and a twelve month high of $36.20. The firm has a market capitalization of $51.00 million, a price-to-earnings ratio of 24.38 and a beta of 1.47. The company has a quick ratio of 0.89, a current ratio of 1.28 and a debt-to-equity ratio of 4.87. The stock’s 50 day moving average price is $4.87 and its two-hundred day moving average price is $13.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Sanuwave Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Sanuwave Health has an average rating of “Reduce” and a consensus price target of $47.00.

About Sanuwave Health

SANUWAVE Health, Inc is a medical technology company focused on regenerative medicine and advanced wound-care solutions. The company develops and commercializes noninvasive devices that use extracorporeal shock wave technology to stimulate biological responses in damaged or difficult-to-heal tissue.

Its principal product is the dermaPACE system, which is designed to deliver acoustic shock waves to wound areas, including chronic diabetic foot ulcers. SANUWAVE has also pursued additional applications for its platform in areas such as orthopedic and soft-tissue healing, although the availability and regulatory status of specific products may vary by geography.

The company serves the wound-care and regenerative-medicine markets through commercial, clinical, and distribution activities in the United States and international markets.